Skip to main content
GALT
NASDAQ Life Sciences

Galectin Seeks Shareholder Nod to Nearly Double Authorized Shares to 250M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.915
Mkt Cap
$394.826M
52W Low
$2.025
52W High
$7.13
52W Position info
93% above low
Off High info
45% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

GALT sits 93% above its 52-week low of $2.025 on light trading volume (0.3× avg).

Summary

Galectin Therapeutics is asking shareholders to approve a 100 million share increase in authorized common stock and an additional 3 million shares for its equity incentive plan, while disclosing Chairman Uihlein's 49.4% ownership stake.


Key Events · Corporate Governance and Compliance · GALT

  • Authorized Share Increase Proposed

    Proposal 2 seeks to increase authorized common shares from 150,000,000 to 250,000,000, adding 100 million shares for potential future issuance.

  • Equity Plan Expansion

    Proposal 3 would reserve an additional 3,000,000 shares under the 2019 Omnibus Equity Incentive Plan, increasing the plan from 10 million to 13 million shares.

  • Limited Remaining Authorized Shares

    If both proposals pass, the company would have only approximately 26 million authorized shares remaining for issuance, excluding shares reserved for outstanding instruments.

  • Chairman's 49.4% Ownership

    Chairman Richard Uihlein beneficially owns 54,831,388 shares, representing 49.4% of common stock, after converting $105.8 million of debt to equity on July 31, 2026.


Analysis · GALT · Life Sciences

The proxy asks shareholders to approve a 100 million share increase in authorized common stock, from 150 million to 250 million. With only about 26 million authorized shares remaining after accounting for the equity plan expansion, the company is signaling it will need to raise capital through equity financings after its current cash runway is exhausted. The filing also discloses that Chairman Richard Uihlein now controls 49.4% of the company after converting $105.8 million of debt to equity in July 2026, giving him significant influence over the vote.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GALT was trading at $3.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $394.8M. The 52-week trading range was $2.03 to $7.13. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GALT - Latest Insights

GALT
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $2.81 info
Change: -$0.290 (-9%) info
Market Cap: $283.459M info
GALT
Nov 16, 2026, 7:50 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.10
Real-time Price: $2.81 info
Change: -$0.290 (-9%) info
Market Cap: $283.459M info
GALT
Oct 13, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $2.81 info
Change: -$1.13 (-29%) info
Market Cap: $283.459M info
GALT
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $2.81 info
Change: -$0.640 (-19%) info
Market Cap: $283.459M info
GALT
Aug 14, 2026, 7:55 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.49
Real-time Price: $2.81 info
Change: -$0.680 (-19%) info
Market Cap: $283.459M info